Affymetrix and Iconix Collaborate to Develop New Solutions for Assessing Drug Toxicity


Affymetrix Inc. and Iconix Pharmaceuticals Inc. announced that the companies have signed a collaborative agreement to develop solutions to aid in the study of the toxicological and pharmacological properties of drugs and drug candidates. The collaboration will aim to significantly accelerate the drug development process by combining Affymetrix' microarray technology with Iconix' compound reference database and analysis software.

Together, Affymetrix' expression arrays and Iconix' analysis methods will provide detailed information on a drug candidate's toxicological liabilities and pharmacological properties. Using such tools, researchers will be able to quickly compare gene expression profiles to the Iconix' Drug Signatures(R) library to help predict the impact that gene expression changes may have on biological pathways critical to the body's toxic response to drugs.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy